

FMNL1 Antibody (Center) Blocking peptide

Synthetic peptide Catalog # BP5551c

Specification

FMNL1 Antibody (Center) Blocking peptide - Product Information

Primary Accession O95466
Other Accession NP_005883.2

FMNL1 Antibody (Center) Blocking peptide - Additional Information

Gene ID 752

Other Names

Formin-like protein 1, CLL-associated antigen KW-13, Leukocyte formin, FMNL1, C17orf1, C17orf1B, FMNL

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

FMNL1 Antibody (Center) Blocking peptide - Protein Information

Name FMNL1

Synonyms C17orf1, C17orf1B, FMNL, FRL1

Function

May play a role in the control of cell motility and survival of macrophages (By similarity). Plays a role in the regulation of cell morphology and cytoskeletal organization. Required in the cortical actin filament dynamics and cell shape.

Cellular Location

Cytoplasm. Cell membrane; Lipid-anchor. Cytoplasmic vesicle, phagosome. Note=Recruited to actin-rich phagosomes during phagocytosis. Translocates to the plasma membrane upon activation by RAC1 (By similarity).

Tissue Location

Expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas



FMNL1 Antibody (Center) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

FMNL1 Antibody (Center) Blocking peptide - Images

FMNL1 Antibody (Center) Blocking peptide - Background

This gene encodes a formin-related protein. Formin-related proteins have been implicated in morphogenesis, cytokinesis, andcell polarity.

FMNL1 Antibody (Center) Blocking peptide - References

Han, Y., et al. J. Biol. Chem. 284(48):33409-33417(2009)Olsen, J.V., et al. Cell 127(3):635-648(2006)Olsen, J.V., et al. Cell 127(3):635-648(2006)